Mental and Behavioural Disorders
Conditions
Interventions
Omega 3 fish oil
Artane
Sponsors
Dr Sammy Ohene
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A confirmed diagnosis of antipsychotic-induced movement disorder Participants aged between 18 and 60years. On a stable dose of antipsychotic medication within 3 months prior to study Patients in the control arm should not have initiated anti-cholinergic therapy Patients should demonstrate a commitment not to initiate or modify interventions during the period of the study.
Exclusion criteria
Exclusion criteria: Patients whose psychiatric disorder was not stable; Patients with a significant organic neurological disorder other than the mental disorder Treatment with omega-3 therapy 3months prior to study Patients who were pregnant or breastfeeding. Patients with a diagnosis of substance dependence (DSM-IV), Patients with a known allergy to omega 3 fish oil or sea foods
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the efficacy and safety of omega 3 1000mg polyunsaturated fatty acid therapy in reducing the severity of symptoms in patients experiencing antipsychotic-induced movement disorders after 24 weeks of supplementation | — |
Secondary
| Measure | Time frame |
|---|---|
| Determine the correlations between omega 3 supplementation and clinical outcomes of therapy after intervention | — |
Countries
Ghana
Contacts
Public ContactFrances Owusu Daaku
Professor Kwame Nkrumah University of Science and Technology
Outcome results
None listed